[Federal Register Volume 88, Number 189 (Monday, October 2, 2023)]
[Notices]
[Pages 67753-67754]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-21567]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC-2023-0082]


Advisory Committee to the Director, Centers for Disease Control 
and Prevention

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of meeting and request for comment.

-----------------------------------------------------------------------

SUMMARY: In accordance with regulatory provisions, the Centers for 
Disease Control and Prevention (CDC) announces the following meeting of 
the Advisory Committee to the Director, Centers for Disease Control and 
Prevention (ACD, CDC). This is a hybrid meeting, accessible both in 
person and virtually (webcast live via the World Wide Web). It is open 
to the public and limited only by the space available. Time will be 
available for public comment.

DATES: The meeting will be held on November 14, 2023, from 9:00 a.m. to 
4:00 p.m., EST (times subject to change).
    Written comments must be received on or before October 27, 2023.

ADDRESSES: 
    Meeting address: CDC Roybal Campus, Building 19, Auditorium B3, 
1600 Clifton Road NE, Atlanta, Georgia 30329-4027.
    Please note that the meeting location, the CDC Roybal Campus, is a 
federal facility and in-person access is limited to United States 
citizens unless prior authorizations, taking up to 30 to 60 days, have 
been made. Visitors must follow all directions for access to CDC 
facilities. Directions for visitors to CDC, including safety 
requirements related to COVID-19; are available at https://www.cdc.gov/screening/visitors.html.
    Registration: You must register to attend this meeting in person. 
If you wish to attend in person, please submit a request by email to 
<a href="/cdn-cgi/l/email-protection#efaeacab869d8a8c9b809daf8c8b8cc1888099"><span class="__cf_email__" data-cfemail="87c6c4c3eef5e2e4f3e8f5c7e4e3e4a9e0e8f1">[email protected]</span></a> or by telephone at (404) 345-1039 at least 5 
business days in advance of the meeting. No registration is required to 
view the meeting via the World Wide Web. Information for accessing the 
webcast will be available at https://www.cdc.gov/about/advisory-committee-director/.
    Written comments: You may submit comments, identified by Docket No. 
CDC-2023-0082, by either of the methods listed below. Do not submit 
comments for the docket by email. CDC does not accept comments for the 
docket by email.
    <bullet> Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments.
    <bullet> Mail: Bridget Richards, MPH, Centers for Disease Control 
and Prevention, 1600 Clifton Road NE, Mailstop H21-10, Atlanta, Georgia 
30329-4027. Attn: Docket No. CDC-2023-0082.
    Instructions: All submissions received must include the agency name 
and Docket Number. All relevant comments received will be posted 
without change to https://www.regulations.gov, including any personal 
information provided. For access to the docket to read background 
documents or comments received, go to https://www.regulations.gov. 
Written comments received in advance of the meeting will be included in 
the official record of the meeting.

FOR FURTHER INFORMATION CONTACT: Bridget Richards, MPH, Office of the 
Chief of Staff, Centers for Disease Control and Prevention, 1600 
Clifton Road NE, Mailstop H21-10, Atlanta, Georgia 30329-4027; 
Telephone: (404) 345-1039; Email: <a href="/cdn-cgi/l/email-protection#743537301d061117001b06341710175a131b02"><span class="__cf_email__" data-cfemail="dc9d9f98b5aeb9bfa8b3ae9cbfb8bff2bbb3aa">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: 
    Purpose: The Advisory Committee to the Director, CDC, shall (1) 
make recommendations to the Director regarding ways to prioritize the 
activities of the agency in alignment with the CDC Strategic Plan 
required under section 305(c); H.R. 2617-1252; (2) advise on ways to 
achieve or improve performance metrics in relation to the CDC Strategic 
Plan, and other relevant metrics, as appropriate; (3) provide advice 
and recommendations on the development of the Strategic Plan, and any 
subsequent updates, as appropriate; (4) advise on grant, cooperative 
agreements, contracts, or other transactions, as applicable; (5) 
provide other advice to the Director, as requested, to fulfill duties 
under sections 301 and 311; and (6) appoint subcommittees. The 
Committee recommends ways to prioritize CDC's activities, improve 
results, and address health disparities. It also provides guidance to 
help CDC work more effectively with its various private and public 
sector constituents to make health protection a practical reality.
    Matters to be Considered: The agenda will include an introduction 
of the new CDC Director, Dr. Mandy Cohen, and a discussion regarding 
agency updates and priorities. The agenda also includes updates on the 
progress made to date on the health equity, laboratory, and data and 
surveillance recommendation; discussion and vote on the Laboratory 
Workgroup final recommendations; and discussion and votes to sunset the 
Health Equity and Laboratory workgroups due to completion of their 
terms of reference. CDC's Senior Advisor for Health Strategy will 
present on supporting healthy families, and a Senior Counselor to the 
CDC Director will present on COVID-19 recission. Agenda items are 
subject to change as priorities dictate.

Public Participation

    Interested persons or organizations are invited to participate by 
submitting written views, recommendations, and data. Please note that 
comments received, including attachments and other supporting 
materials, are part of the public record and are subject to public 
disclosure. Comments will be posted on https://www.regulations.gov. 
Therefore, do not include any information in your comment or supporting 
materials that you consider confidential or inappropriate for public 
disclosure. If you include your name, contact information, or other 
information that identifies you in the body of your comments, that 
information will be on public display. CDC will review all submissions 
and may choose to redact, or withhold, submissions containing private 
or proprietary information such as Social Security numbers, medical 
information, inappropriate language, or duplicate/near duplicate 
examples of a mass-mail campaign. CDC will carefully consider all 
comments submitted into the docket.
    Written Public Comment: The docket will be opened to receive 
written comments on October 2, 2023 through October 27, 2023.
    The Director, Office of Strategic Business Initiatives, Office of 
the Chief Operating Officer, Centers for Disease Control and 
Prevention, has been delegated the authority to sign Federal Register 
notices pertaining to announcements of meetings and other

[[Page 67754]]

committee management activities, for both the Centers for Disease 
Control and Prevention and the Agency for Toxic Substances and Disease 
Registry.

Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-21567 Filed 9-29-23; 8:45 am]
BILLING CODE 4163-18-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>